Archive for May 2022
Nasodine now patented in 26 countries
Firebrick’s core patent covering Nasodine® Nasal Spray is now granted in 26 countries Firebrick Pharma is pleased to announce that its patent covering Nasodine® Nasal Spray (“Nasodine”) as a treatment and preventative for the common cold has now been granted in Malaysia. This brings the number of countries where Firebrick’s common cold patent has been…
Firebrick appoints Dr Richard Treagus as director
Dr Richard Treagus is an important appointment to the FRE board Dr Treagus is a medical doctor with extensive ASX experience and a valuable background in pharmaceutical sales and marketing Most recently, Dr Treagus was Executive Chairman of Neuren Pharmaceuticals (ASX: NEU), a successful Australian biotech company Firebrick Pharma is pleased to announce the appointment…
Channel 7 shines a spotlight on Firebrick’s Phase 3 common cold trial for Nasodine
Firebrick Pharma’s Dr Peter Molloy and Dr Chris Rock from CMAX Clinical Research discuss with Channel 7 the start of our Phase 3 common cold trial for Nasodine® Nasal Spray. Adelaide is the first location for the trial, with sites in Victoria and South Africa to follow. If you live in South Australia or Victoria,…
Peter Molloy discusses the common cold trial on global finance platform Grafa
Firebrick Pharma Executive Chairman Peter Molloy discusses our common cold trial on international finance platform Grafa following the recruitment of our first patient.
Nasodine Phase 3 common cold trial underway
Firebrick Pharma is pleased to announce that the first patient has been recruited into its confirmatory Phase 3 trial for Nasodine® Nasal Spray (“Nasodine”) as a treatment for the common cold. The randomised controlled Phase 3 trial expects to recruit up to 450 adult subjects with early cold symptoms to achieve a target treatment population…